News related to Lucentis (Ranibizumab) and/or conditions it is approved for
Novartis announce licence change for leading sight loss treatment Lucentis® (ranibizumab)
Source: Eye Health / Blindness News From Medical News Today [2014.09.25]
Novartis has announced a change to the licence of Lucentis® (ranibizumab), which means treatment can now be offered without the need for monthly monitoring in patients with stable disease...
UK data presented at EURETINA 2014 showcase efficacy of EYLEA in clinical practice for the treatment of wet age-related macular degeneration
Source: Eye Health / Blindness News From Medical News Today [2014.10.05]
Bayer HealthCare reports that data have been presented at the 14th EURETINA congress in London, showcasing the efficacy of EYLEA® (aflibercept solution for injection) for the treatment of wet...
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2014.01.23]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 6:05:00 PM
Last Editorial Review: 1/23/2014 12:00:00 AM
'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
Source: MedPageToday.com - medical news plus CME for physicians [2014.10.18]
(MedPage Today) -- This week's topics include fecal transplant capsules, stem cells for macular degeneration, exercise and depression in teens, and Ebola predictions.
Three-year data from Oraya Therapeutics' INTREPID study continue to show favorable safety profile of non-invasive wet AMD therapy
Source: Eye Health / Blindness News From Medical News Today [2014.09.17]
Oraya Therapeutics Inc. has announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further...